Alnylam Pharmaceuticals (ALNY) Other Working Capital Changes (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 10 years of Other Working Capital Changes data on file, last reported at $8.3 million in Q2 2026.

• Quarterly Other Working Capital Changes rose 163.29% year-over-year to $8.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.0 million (up 101.84% YoY) and the FY2025 annual result came in at -$50.6 million, up 78.49% from the prior year.
• Other Working Capital Changes grew to $8.3 million in Q2 2026, from $3.0 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $75.5 million in Q1 2024 to a low of -$61.7 million in Q2 2024.
• A 5-year average of $12.7 million and a median of $7.3 million in 2024 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2023 — Other Working Capital Changes soared 694.9% — and 2024, when it slumped 1632.7%.
• Tracing ALNY's Other Working Capital Changes over 5 years: stood at -$34.2 million in 2022, then surged by 151.73% to $17.7 million in 2023, then slumped by 172.42% to -$12.8 million in 2024, then jumped by 117.99% to $2.3 million in 2025, then surged by 259.13% to $8.3 million in 2026.
• The last three Other Working Capital Changes figures came in at $8.3 million (Q2 2026), $3.0 million (Q1 2026), and $2.3 million (Q4 2025), per Business Quant data.